Physician profile
Anabel Jimenez
NPI 1932717998
$3,667.67
in general payments reported to CMS, 2019-2025
20 companies · $17.01 in 2025
The $17.01 reported for 2025 was less than what a typical Primary Care provider received nationally (typical 2025 total: $170).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $366 · 2023: $2,029 · 2024: $1,255 · 2025: $17.01.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,278 · Education: $23.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,277.95 |
| Education | $23.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $688.17 | 2022-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $530.74 | 2022-2024 | Relistor |
| Medtronic, INC. | $438.22 | 2023-2024 | Intellis Adaptivestim, Synchromedii |
| Curonix LLC | $387.18 | 2023-2024 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Collegium Pharmaceutical, INC. | $320.38 | 2022-2024 | Xtampza, Belbuca |
| Abbott Laboratories | $190.43 | 2023 | Proclaim |
| Nalu Medical, INC. | $163.66 | 2023-2024 | Nalu Neurostimulation System |
| Pfizer INC. | $156.65 | 2023-2024 | |
| Tersera Therapeutics LLC | $143.74 | 2024 | Prialt |
| E.R. Squibb & Sons, L.L.C. | $121.13 | 2022 | |
| Evoke Pharma, INC. | $117.92 | 2024 | |
| Scilex Pharmaceuticals INC. | $113.38 | 2023-2024 | Ztlido |
| Ibsa Pharma INC. | $97.86 | 2023 | Tirosint, Licart |
| Azurity Pharmaceuticals, INC. | $75.10 | 2023 | Horizant |
| Mvp Orthopedics INC | $28.50 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $25.37 | 2023 | Senza |
| Almatica Pharma LLC | $21.23 | 2022 | |
| Boston Scientific Corporation | $17.26 | 2024 | |
| Amgen INC. | $17.01 | 2025 | Otezla |
| Kowa Pharmaceuticals America, INC. | $13.74 | 2023 | Seglentis |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anabel Jimenez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.